TABLE 2.
Bacterial strains used in this study
| Name | Genotype | Resistance marker(s) | Reference or source |
|---|---|---|---|
| E. coli | |||
| DH5α | F− endA1 glnV44 thi-1 recA1 relA1 gyrA96 deoR nupG purB20 ϕ80dlacZΔM15 Δ(lacZYA-argF)U169 hsdR17(rK− mK+) λ− | Invitrogen | |
| BL21(DE3) | B strain; F− ompT gal dcm lon hsdSB(rB− mB−) λ(DE3 [lacI lacUV5-T7p07 ind1 sam7 nin5]) [malB+]K-12 (λS) | Invitrogen | |
| SCS110 | endA mutant derivative of the JM110 strain; rpsL (Strr) thr leu endA thi-1 lacY galK galT ara tonA tsx dam dcm supE44 Δ(lac-proAB) [F′ traD36 proAB lacIqZΔM15] | Stratagene | |
| B. anthracis Sterne 34F2 | |||
| BAS WT | pXO1+, pXO2− | NIAID, NIH | |
| BAS ΔprkC | ΔprkC | Kanamycin | 42 |
| BAS ΔprkC::prkC | ΔprkC::prkC | Kanamycin, spectinomycin | This study |
| BAS WT::bslO | Sterne::bslO | Kanamycin | This study |